Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.

Murányi J, Varga A, Gyulavári P, Pénzes K, Németh CE, Csala M, Pethő L, Csámpai A, Halmos G, Peták I, Vályi-Nagy I.

Int J Mol Sci. 2019 Nov 8;20(22). pii: E5590. doi: 10.3390/ijms20225590.

2.

Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers.

Pethő L, Murányi J, Pénzes K, Gurbi B, Brauswetter D, Halmos G, Csík G, Mező G.

Int J Mol Sci. 2019 Oct 11;20(20). pii: E5027. doi: 10.3390/ijms20205027.

3.

Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy.

Boros-Oláh B, Dobos N, Hornyák L, Szabó Z, Karányi Z, Halmos G, Roszik J, Székvölgyi L.

DNA Repair (Amst). 2019 Dec;84:102642. doi: 10.1016/j.dnarep.2019.102642. Epub 2019 Jul 6.

4.

Corrigendum: RNA-DNA hybrid (R-loop) immunoprecipitation mapping: an analytical workflow to evaluate inherent biases.

Halász L, Karányi Z, Boros-Oláh B, Kuik-Rózsa T, Sipos É, Nagy É, Mosolygó-L Á, Mázló A, Rajnavölgyi É, Halmos G, Székvölgyi L.

Genome Res. 2019 Jan;29(1):157. doi: 10.1101/gr.246652.118. No abstract available.

5.

Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification.

Schuster S, Biri-Kovács B, Szeder B, Buday L, Gardi J, Szabó Z, Halmos G, Mező G.

Pharmaceutics. 2018 Nov 9;10(4). pii: E223. doi: 10.3390/pharmaceutics10040223.

6.

Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).

Oláh G, Dobos N, Vámosi G, Szabó Z, Sipos É, Fodor K, Harda K, Schally AV, Halmos G.

Eur J Pharm Sci. 2018 Oct 15;123:371-376. doi: 10.1016/j.ejps.2018.08.002. Epub 2018 Aug 2.

PMID:
30076951
7.

Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.

Harda K, Szabo Z, Szabo E, Olah G, Fodor K, Szasz C, Mehes G, Schally AV, Halmos G.

Molecules. 2018 Jun 26;23(7). pii: E1535. doi: 10.3390/molecules23071535.

8.

Synthesis and in vitro biochemical evaluation of oxime bond-linked daunorubicin-GnRH-III conjugates developed for targeted drug delivery.

Schuster S, Biri-Kovács B, Szeder B, Farkas V, Buday L, Szabó Z, Halmos G, Mező G.

Beilstein J Org Chem. 2018 Apr 4;14:756-771. doi: 10.3762/bjoc.14.64. eCollection 2018.

9.

Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines.

Sipos E, Dobos N, Rozsa D, Fodor K, Olah G, Szabo Z, Szekvolgyi L, Schally AV, Halmos G.

Onco Targets Ther. 2018 Feb 22;11:933-941. doi: 10.2147/OTT.S148174. eCollection 2018.

10.

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy.

Hornyák L, Dobos N, Koncz G, Karányi Z, Páll D, Szabó Z, Halmos G, Székvölgyi L.

Front Immunol. 2018 Jan 31;9:151. doi: 10.3389/fimmu.2018.00151. eCollection 2018. Review.

11.

Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma.

Sipos E, Hegyi K, Treszl A, Steiber Z, Mehes G, Dobos N, Fodor K, Olah G, Szekvolgyi L, Schally AV, Halmos G.

Oncol Rep. 2017 Apr;37(4):1927-1934. doi: 10.3892/or.2017.5496. Epub 2017 Mar 8.

12.

RNA-DNA hybrid (R-loop) immunoprecipitation mapping: an analytical workflow to evaluate inherent biases.

Halász L, Karányi Z, Boros-Oláh B, Kuik-Rózsa T, Sipos É, Nagy É, Mosolygó-L Á, Mázló A, Rajnavölgyi É, Halmos G, Székvölgyi L.

Genome Res. 2017 Jun;27(6):1063-1073. doi: 10.1101/gr.219394.116. Epub 2017 Mar 24. Erratum in: Genome Res. 2019 Jan;29(1):157.

13.

Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.

Zarandi M, Cai R, Kovacs M, Popovics P, Szalontay L, Cui T, Sha W, Jaszberenyi M, Varga J, Zhang X, Block NL, Rick FG, Halmos G, Schally AV.

Peptides. 2017 Mar;89:60-70. doi: 10.1016/j.peptides.2017.01.009. Epub 2017 Jan 24.

PMID:
28130121
14.

Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC.

Szabó Z, Szegedi K, Gombos K, Mahua C, Flaskó T, Harda K, Halmos G.

Urol Oncol. 2016 Dec;34(12):533.e21-533.e27. doi: 10.1016/j.urolonc.2016.06.011. Epub 2016 Jul 15.

PMID:
27427222
15.

Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.

Szabó I, Bősze S, Orbán E, Sipos É, Halmos G, Kovács M, Mező G.

J Pept Sci. 2015 May;21(5):426-35. doi: 10.1002/psc.2775. Epub 2015 Apr 24.

PMID:
25908176
16.

Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.

Mezey G, Treszl A, Schally AV, Block NL, Vízkeleti L, Juhász A, Klekner A, Nagy J, Balázs M, Halmos G, Bognár L.

J Cancer Res Clin Oncol. 2014 Oct;140(10):1641-9. doi: 10.1007/s00432-014-1716-1. Epub 2014 Jun 1.

PMID:
24878932
17.

A rare case of Asherman's syndrome after open myomectomy: sonographic investigations and possible underlying mechanisms.

Papoutsis D, Georgantzis D, Daccò MD, Halmos G, Moustafa M, Mesquita Pinto AR, Magos A.

Gynecol Obstet Invest. 2014;77(3):194-200. doi: 10.1159/000357489. Epub 2014 Feb 15.

PMID:
24557451
18.

Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities.

Cai R, Schally AV, Cui T, Szalontay L, Halmos G, Sha W, Kovacs M, Jaszberenyi M, He J, Rick FG, Popovics P, Kanashiro-Takeuchi R, Hare JM, Block NL, Zarandi M.

Peptides. 2014 Feb;52:104-12. doi: 10.1016/j.peptides.2013.12.010. Epub 2013 Dec 25.

19.

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.

Treszl A, Steiber Z, Schally AV, Block NL, Dezso B, Olah G, Rozsa B, Fodor K, Buglyo A, Gardi J, Berta A, Halmos G.

Oncotarget. 2013 Oct;4(10):1721-8.

20.

Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.

Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A, Rick FG.

Oncotarget. 2013 May;4(5):751-60.

Supplemental Content

Loading ...
Support Center